

Possible selection of host folate pathway gene polymorphisms in patients with malaria from a malaria endemic region in North East India

Darshana Mirgal^a, Kanjaksha Ghosh^b, Jagadish Mahanta^c, Prafulla Dutta^c and Shrimati Shetty^{a,*}

^aDepartment of Hemostasis and Thrombosis, National Institute of Immunohaematology (ICMR), New Multistoreyed Building, KEM Hospital, Parel, Mumbai; ^bSurat Raktadan Kendra and Research Center, Gujarat; ^cRegional Medical Research Centre (ICMR), Dibrugarh, Assam

*Corresponding author: Tel: +91 22 24138518/19; Fax: +91 22 24138521; E-mail: shrimatishetty@yahoo.com

Received 19 November 2015; revised 24 February 2016; accepted 23 March 2016

Background: Recent studies in experimental mice have shown that mild deficiency of methylenetetrahydrofolate reductase (MTHFR) enzyme confers protection against malaria, thus providing an important basis for the hypothesis that MTHFR polymorphism, i.e. C677T, might have been subjected to selection pressure against malaria. The present study was undertaken in a malaria endemic region in North East India to assess whether a similar selection advantage exists for other genes in folate metabolism pathway.

Methods: A total of 401 subjects including 131 symptomatic malaria, 97 asymptomatic malaria and 173 normal healthy controls were analysed for nine polymorphisms (single-nucleotide polymorphisms [SNPs] in eight genes and insertion/deletion in one gene): MTHFR C677T, methionine synthase reductase (MTRR) A66G, glutamate carboxypeptidase II (GCPII) C1561T, cystathionine beta-synthase (CBS) 844ins68, reduced folate carrier-1 (RFC-1) G80A, serine hydroxymethyltransferase (SHMT) C1420T, methionine synthase (MTR) A2756G, MTHFR G1793A (D 919G), glycine N-methyltransferase (GNMT) 1289 by PCR-RFLP technique. Differences in frequencies of genotype distribution of each polymorphic marker between these groups were evaluated.

Results: MTRR A2756G, SHMT C1420T, GCPII C1561T, MTRR A2756G and GNMT C1289T and RFC1 G80A polymorphisms showed significantly different prevalence between different groups analyzed. No significant differences were seen in the distribution of other polymorphisms.

Conclusions: The study gives a clue for the possible selection of specific polymorphisms in the genes involved in the folate metabolism pathway by malaria parasite.

Keywords: Folate metabolism pathway polymorphisms, India, Malaria, MTHFR, Selection

Introduction

The major cause of mortality among children worldwide is malaria, which annually kills more than 1 million children in Africa alone and is estimated to cause about half a billion episodes of disease each year due to *Plasmodium falciparum* infection only.¹ Malaria is unique in that it has exerted the strongest known selective pressure to the human genome.² The classic example is HbS allele which has risen due to the high frequencies in malaria exposed populations, despite the fact that homozygotes have high mortality.³ The different geographic distribution of α thalassemia, G6PD deficiency and Duffy negative blood groups are a few other examples of the general principle that different populations have selected different polymorphisms to protect from malaria parasite.^{3,4}

All mammals require folate metabolism to recycle methionine and homocysteine. Malarial parasites are capable of de novo folate synthesis and they also have hydrofolate reductase which is more sensitive to antimalarial inhibitors than that of the host cell.⁵ There are also reports which suggest that breakdown products of folate may be used by parasites for this de novo synthesis.⁶ Thus it is possible that if the parasite has restricted folate cycle, as mentioned above, it might depend on more complete host cell folate cycle to carry out other reactions such as metabolism of increased levels of homocysteine produced by methionine use. When there is concurrent occurrence of methylenetetrahydrofolate reductase (MTHFR) mutation, folate/vitamin B6/B12 deficiency combined with high methionine use by malarial parasite, there may be acute imbalance in

were analyzed using previously reported primers^{19,23–25} (Sigma Aldrich, St. Louis, MO, USA) (Supplementary Table 1) with or without restriction enzyme digestion. All PCR amplifications were carried out in GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). The amplified products were run on 2% agarose gel (Invitrogen, Bengaluru, India). Wherever required, PCR products were digested with specific restriction enzymes (Fermentas, Baltimore MD, USA) (Supplementary Table 1). The digested products were analysed by 10% polyacrylamide gel electrophoresis (PAGE).

Statistical analysis

The data was analyzed using MedCalc Statistical online software version 15.8 (MedCalc Software bvba, Ostend, Belgium). The differences in prevalence were analyzed using the Fishers exact test. A difference with a p-value ≤ 0.05 was considered statistically significant.

Results

A total of 401 samples which included 131 symptomatic, 97 asymptomatic malaria and 173 normal healthy controls from the same geographical region were tested for folate metabolism pathway related polymorphisms.

When symptomatic and asymptomatic malaria patients were compared, three polymorphisms i.e. serine hydroxymethyltransferase (SHMT) C1420T, methionine synthase reductase (MTRR) A2756G and glycine N-methyltransferase (GNMT) C1289T were found to be significantly different between the two groups ($p < 0.05$). When compared between patients with malaria and normal controls, SHMT C1420T, MTRR A2756G, GNMT C1289T were still significantly different between the two groups. In addition, MTRR A66G, reduced folate carrier-1 (RFC-1) G80A and cystathionine β -synthase (CBS) 844ins68 polymorphisms were different between the two groups (Table 1). About one-third of the controls had the RFC1 G80A polymorphism which was not found in any of the patients with

Table 1. Polymorphisms analyzed in the present study

Polymorphisms	Variants	Asymptomatic patients	Symptomatic patients	p-value	Controls	Total malaria patients	p-value
MTHFR C677T	CC	72	99	NS	127	171	NS
	CT	23	32		43	55	
	TT	2	0		3	2	
MTRR 66AG	AA	20	34	NS	66	54	0.0019
	AG	77	97		98	174	
	GG	0	0		9	0	
GCP II C1561T	CC	97	131	NS	168	228	NS
	CT	0	0		5	0	
	TT	0	0		0	0	
CBS 844ins68	Insertion negative	92	121	NS	173	213	0.0251
	Insertion positive	5	10		0	15	
RFC I G80A	GG	24	44	NS	10	68	<0.0001
	GA	73	87		105	160	
	AA	0	0		58	0	
SHMT C1420T	CC	24	16	0.0156	89	40	<0.0001
	CT	73	115	0.0156	84	188	<0.0001
	TT	0	0	NS	0	0	NS
MTRR A2756G	AA	10	79	<0.0001	146	89	0.0001
	AG	78	43	<0.0001	27	121	<0.0001
	GG	9	9	0.3794	0	18	0.0174
MTHFR G1793A	GG	69	94	NS	128	163	NS
	GA	28	37		45	65	
	AA	0	0		0	0	
GNMT C1289T	CC	44	78	0.0344	89	122	NS
	CT	31	24	0.0185	21	55	0.0029
	TT	22	29	NS	63	51	0.0022

CBS: cystathionine beta-synthase; GNMT: glycine N-methyltransferase; MTHFR: methylenetetrahydrofolate reductase; MTR: methionine synthase; MTRR: methionine synthase reductase; NS: not significant; RFC1: reduced folate carrier-1.

malaria. Table 1 shows the distribution of the genotypes and alleles in different groups.

Discussion

This is the first report of a comprehensive analysis of folate metabolism pathway polymorphisms in association with malaria infection. Despite several eradication programmes across the globe, malaria still continues to prevail causing an estimated 560 000 deaths per year, mostly children under 5 years of age. In malaria endemic regions, total eradication has still not been possible due to several reasons, the most important being the presence of patients with asymptomatic malaria, who do not seek medical treatment.²⁶ The presence of higher incidence of asymptomatic malaria in any part of the world is a big challenge and a serious concern for malaria control programmes; it may serve as a reservoir for continued transmission, and may further complicate diagnosis.

Asymptomatic malaria is a known phenomenon in malaria-endemic areas with high transmission.²⁷ It is associated with low parasite densities, usually observed in patients later in life living in high endemic areas after repeated infections of malaria and has been attributed to different factors, some of which include development of acquired immunity to *P. falciparum*.²⁸

There are reports to show that host parasite interaction plays a major role in the selection of malaria parasite during evolution.²⁹ Host factors also play an important role in this selection process. For instance, erythrocytes are protected from increased infection by the malarial parasite through the up regulation of a hormone, i.e., hepcidin.³⁰ Hepcidin induction during infection causes depletion of extracellular iron, which is presumably a general defence mechanism against infections by withholding iron from invading parasites. This implies that the host parasite interaction will be altered if the host iron levels are altered.

The interaction between folate metabolism and malaria parasite is very well known. Among the folate pathway polymorphisms, MTHFR C677T polymorphism has been extensively investigated for its association with various pathogenic conditions including recurrent fetal loss, Down syndrome and neural tube defects.¹²⁻¹⁵ In a recent study, MTHFR deficient mice and MTHFR over expressing mice were infected with *Plasmodium berghei* ANKA to induce cerebral malaria. MTHFR mice survived longer than MTHFR overexpressing mice.¹⁷ A similar result was obtained earlier in the knockout mice (Mthfr^{-/-} mice) to cytomegalovirus.³¹ The data clearly suggests that mild MTHFR deficiency protects against severe malaria and that this phenomenon may have led to the high frequency of the C677T variant in human populations across the world.

In the present study MTRR A2756G polymorphism showed significantly different prevalence between the asymptomatic (80.4%, 78/97) and symptomatic (32.8%, 43/131) malaria groups and between malaria patients and controls ($p=0.0001$). Surprisingly, the RFC-1 G80A homozygotes were absent in malaria patients (0%) as compared to one-third of the normal healthy controls (33.5%, 58/173). RFC-1 is important in folate metabolism and it helps in active transport of 5-methyltetrahydrofolate from the plasma to the cytosol. It also facilitates movement of folate and thiamine monophosphate across the cell membrane, thus maintaining an optimum level of folate both within and outside

the cells.³² Polymorphisms in this gene are known to affect its binding with folate.³³ In addition, RFC-1 also plays an important role in folate homeostasis where it gets down-regulated in response to folate deficiency.³⁴ The gene is highly polymorphic and has been found to be associated with different diseases like ischemic stroke, neural tube defects and different types of cancers.

The study has several limitations. First, no phenotype-genotype association could be made in the present study. Second, the sample size is small in each group to draw a definitive conclusion. Third, molecular tools were not used to detect low density parasitemia in both asymptomatic patients and normal healthy controls. Despite these limitations, the study highlights the need for extension of these studies to other populations in malaria endemic regions in this country.

Conclusions

In conclusion, the genotype frequencies of SHMT C1420T, MTRR A2756G and GNMT C1289T were found significantly different between symptomatic and asymptomatic malaria and between patients with malaria and normal healthy controls in the same geographical region. The MTRR A66G, RFC1 G80A and CBS 844ins68 polymorphisms also showed significantly different prevalences between normal controls and patients with malaria. The RFC-1 G80A polymorphism was totally absent in patients with malaria as compared to one-third of normal controls. Whether these polymorphisms were subjected to a selection pressure similar to MTHFR will only be confirmed in large studies in malaria endemic regions.

Supplementary data

Supplementary data are available at Transactions online (<http://trstmh.oxfordjournals.org/>).

Authors' contributions: MD performed the laboratory experiments and analyzed the data; MJ, DP performed the clinical examination of the patients; GK, SS and MJ designed the study and wrote the manuscript. All authors read and approved the final manuscript. SS is guarantor of the paper.

Funding: The project was funded by Department of science and technology (DST) [Grant no. SR/SO/HS 107/2009].

Competing interests: None declared.

Ethical approval: The project was approved by institutional ethics committee of both National Institute of Immunohematology, Mumbai and Regional Medical Research Centre, Dibrugar.

References

- 1 Snow RW, Gurerra CA, Noor AM et al. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature* 2005;434: 214-7.

- 2 Tishkoff SA, Williams SM. Genetic analysis of African population human evolution and complex disease. *Nat Rev Gen* 2002;3:611–21.
- 3 Dominic P, Kwiatkowski. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am J Hum Genet* 2005;77:171–92.
- 4 Tournamilli C, Colon Y, Carttron JP et al. Description of a GATA motif gene expression in Duffy negative individuals. *Nat Genet* 1995;10:224–8.
- 5 Beagly B, Yang TL, Hung J et al. The Glysin 1289 C-T variant influences plasma total homocysteine concentrations on young women after restricting folate intake. *J Nutr* 2005;135:2780–5.
- 6 Dittrich S, Mitchell SL, Blagborough AM et al. An atypical orthologue of 6-pyruvoyltetrahydropterin synthase can provide the missing link in the folate biosynthesis pathway of malaria parasites. *J Nutr* 2008;67:609–18.
- 7 Hebbring SJ, Chai Y, Ji Y et al. Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. *J Neurochem* 2012;120:881–90.
- 8 Ji Y, Nordgren KK, Chai Y et al. Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. *Drug Metab Dispos* 2012;40:1984–92.
- 9 Chillemi R, Zappacosta B, Simporè J et al. Hyperhomocysteinemia in acute *Plasmodium falciparum* malaria: an effect of host-parasite interaction. *Clin Chim Acta* 2004;348:113–20.
- 10 Locke AE, Dooley KJ, Tinker SW et al. Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down Syndrome. *Genet Epidemiol* 2010;34:613–23.
- 11 Nguyen TT, Dyer DL, Dunning DD et al. Human intestinal folate transport: cloning, expression, and distribution of complementary RNA. *Gastroenterology* 1997;112:783–91.
- 12 Chen J, Stampfer MJ, Ma J et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. *Atherosclerosis* 2001;154:667–72.
- 13 Sharp L, Little J. Polymorphism in genes involved in folate metabolism and colorectal neoplasia: A HuGE review. *Am J Epidemiol* 2004;159:423–4.
- 14 Wilson A, Platt R, Wu Q et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. *Mol Genet Metab* 1999;67:317–23.
- 15 O'Leavy VB, Parle-McDermott A, Molloy AM et al. MTRR and MTHFR polymorphisms, link to Down syndrome? *Am J Med Genet* 2002;107:151–5.
- 16 Romero-Sánchez C, Gómez-Gutierrez A, Gómez PE et al. C677T (RS1801133) MTHFR gene polymorphism frequency in a Colombian population. *Colomb Med (Cali)* 2015;46:75–9.
- 17 Meadows DN, Pyzik M, Wu Q et al. Increased resistance to malaria in mice methylenetetrahydrofolate reductase (MTHFR) deficiency suggests a mechanism for selection of the MTHFR 677C>T(c.665C>T) variant. *Hum Mutat* 2014;35:594–600.
- 18 Hobbs CA, Sherman SL, Yi P et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. *Am J Hum Genet* 2000;67:623–30.
- 19 Relton CL, Wilding CS, Pearce MS et al. Gene-gene interaction in folate-related genes and risk of neural tube defects in a UK population. *J Med Genet* 2004;41:256–60.
- 20 Denise L, Doolan, Carlota Doban, J. Kevin Baird. Acquired immunity to malaria. *Clin Microbiol Rev* 2009;22:13–36.
- 21 Manser M, Olufsen C, Andrews N, Chiodini PL. Estimating the parasitaemia of *Plasmodium falciparum*: experience from a national EQA scheme. *Malar J* 2013;12:428.
- 22 Apinijoh TO, Anchang-Kimbi JK, Njua-Yafi C et al. Association of candidate gene polymorphisms and TGF-beta/IL-10 levels with malaria in three regions of Cameroon: a case-control study. *Malar J* 2014;13:236.
- 23 Li Aifan, Zheng Hong, Xu Yuming et al. The association between gene polymorphisms of homocysteine metabolism-related enzymes and ischemic cerebrovascular diseases in Chinese Henan Han population. *Life Sci J* 2012;9:403–8.
- 24 Bonsch D, Bayerlein K, Reulbach U et al. Different allele-distribution of mthfr 677 C -> T and mthfr -393 C ->a in patients classified according to subtypes of Lesch's typology. *Alcohol Alcohol* 2006;41:364–7.
- 25 Beagle B, Yang TL, Hung J et al. The glycine N-methyltransferase (GNMT) 1289 C->T variant influences plasma total homocysteine concentrations in young women after restricting folate intake. *J Nutr* 2005;135:2780–5.
- 26 Lindblade KA, Steinhart L, Samuels A et al. The silent threat: asymptomatic parasitemia and malaria transmission. *Expert Rev Anti Infect Ther* 2013;11:623–39.
- 27 Nkoghe D, Akue JP, Gonzalez JP, Leroy EM. Prevalence of *Plasmodium falciparum* infection in asymptomatic rural Gabonese populations. *Malar J* 2011;10:33.
- 28 Steenkeste N, Rogers WO, Okell L et al. Sub-microscopic malaria cases and mixed malaria infection in a remote area of high malaria endemicity in Rattanakiri province Cambodia: implication for malaria elimination. *Malar J* 2010;9:108.
- 29 Lelliott PM, McMorran BJ, Foote SJ, Burgio G. The influence of host genetics on erythrocytes and malaria infection: is there therapeutic potential? *Malar J* 2015;14:289.
- 30 Portugal S, Carret C, Recker M et al. Host-mediated regulation of superinfection in malaria. *Nat Med* 2011;17:732–7.
- 31 Fodil-Cornu N, Kozij N, Wu Q et al. Methylenetetrahydrofolate reductase (MTHFR) deficiency enhances resistance against cytomegalovirus infection. *Genes Immun* 2009;10:662–6.
- 32 Zhao R, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. *Annu Rev Nutr* 2011;31:177–201.
- 33 Chango A, Emery-Fillon N, de Courcy GP et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. *Mol Genet Metab* 2000;70:310–5.
- 34 Ifergan I, Jansen G, Assaraf YG. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. *J Biol Chem* 2008;283:20687–95.